The medium-chain triglyceride–supplemented KD was feasible in very mild (clinical dementia rating [CDR] 0.5) and mild (CDR 1) Alzheimer’s disease participants, as 10 of 11 participants adhered to the dietary protocol.
The medium chain triglyceride-supplemented KD was not feasible in moderate (CDR 2) Alzheimer’s disease participants as all four of these participants withdrew from the study.
Dietary compliant participants had a 4.1-point mean improvement on Alzheimer’s Disease Assessment Scale-cognitive subscale scores from baseline to the end of the diet. Alzheimer’s Disease Assessment Scale-cognitive subscale improvements diminished after a 1-month diet washout period.
This pilot trial justifies KD studies in mild Alzheimer’s disease.